What Are Contingent Value Rights (CVRs)? Meaning, Types, and Risks
By Markets & Investing DeskUpdated Nov 10, 2026
Definition
A contingent value right is a contractual right, usually given to a target's shareholders in an acquisition, that pays extra cash or stock only if a set event happens before a deadline.
Key takeaways
- CVRs are issued mainly in mergers, acquisitions, restructurings and buyouts to bridge a gap between what the buyer will pay now and what the seller believes the company is worth.
- Payment depends on a trigger, such as a regulatory approval, a sales milestone or the acquirer's share price on a given date.
- Some CVRs trade on an exchange; many are non-transferable.
A contingent value right (CVR) is a contractual right, usually given to a target company’s shareholders in an acquisition, that pays additional cash or stock only if a specified future event happens before a set deadline. If the event does not occur in time, the CVR expires worthless.
What contingent value rights are
When two companies negotiate a deal, they often disagree on the target’s value. The target may point to a drug in late-stage trials, a new technology or a pending contract. The buyer may accept that potential exists but refuse to pay for it in full before it is proven.
A CVR settles that disagreement with a conditional promise. The acquirer pays a fixed price at closing, and the target’s shareholders also receive a right to a further payment if the uncertain outcome materializes. In effect, part of the acquirer’s risk moves to the target’s shareholders, who accept a lower guaranteed price in exchange for upside.
Outside corporate finance, “CVR” has an unrelated meaning: in marketing and e-commerce it stands for conversion rate, the share of visitors who complete a desired action.
How CVRs work
A CVR is created by a written agreement, typically signed alongside the merger agreement, that sets out:
- The trigger: the event that must occur (an approval, a filing, a revenue threshold, a price level).
- The deadline: the date by which the trigger must happen. Like an option, every CVR has an expiration date.
- The payment: a fixed cash amount, a variable amount, or additional shares of the acquirer.
- Transferability: whether holders can sell the right or must keep it.
If the trigger is met within the time frame, holders receive the payment. If not, the right lapses, and shareholders end up with only the cash or stock they received at closing.
Event-driven and price-protection CVRs
Event-driven (milestone) CVRs pay when the acquired business reaches a goal. They are common in pharmaceutical and biotech deals, where the value of a target often hinges on whether a product wins regulatory approval or reaches a sales level.
Price-protection CVRs appear when the acquirer pays with its own stock. They compensate target shareholders if the acquirer’s share price falls below a set level by a predetermined date, paid either in cash or in extra shares. This shields sellers from a drop in the value of the stock they accepted as payment.
Traded vs. non-transferable CVRs
Exchange-traded CVRs are listed and can be bought by anyone, not only former shareholders of the target. An investor can buy or sell them until expiration, and their market price reflects the market’s view of the odds and timing of payment.
Non-transferable CVRs go only to shareholders of the target at the time of the merger and cannot be sold. Companies tend to prefer this form because listing a CVR on an exchange involves more regulatory work and higher cost. The practical consequence for investors: to receive a non-transferable CVR, you must own the target’s stock before the deal closes and the shares are delisted.
Valuing a CVR
A CVR’s value is not known when it is issued, but it can be estimated. For a simple milestone CVR with one fixed payment:
CVR value ≈ (probability of trigger × payment) ÷ (1 + discount rate)^years until payment
This is a probability-weighted net present value calculation. The probability and discount rate are the analyst’s assumptions, not facts in the agreement.
Hypothetical example (milestone CVR): An acquirer offers $40 per share in cash plus one CVR paying $5 if a drug is approved within two years. Assume a 40% chance of approval on time and a 10% annual discount rate.
- Expected payment: 0.40 × $5 = $2.00
- Present value: $2.00 ÷ 1.10² = $2.00 ÷ 1.21 ≈ $1.65
- Estimated total consideration: $40 + $1.65 ≈ $41.65 per share
The headline “$45 per share” (cash plus maximum CVR) overstates what a shareholder can count on. Only the $40 is certain.
Hypothetical example (price-protection CVR): An acquirer pays in shares valued at $50 and issues a CVR covering any shortfall below $50 on a measurement date, with a floor of $40 (maximum payment $10).
Payment = min($10, max($0, $50 − measured share price))
At a measured price of $46, the CVR pays $4. At $35, it pays the $10 maximum, and the shareholder absorbs the remaining loss. At $52, it pays nothing.
Real-world examples
AstraZeneca and CinCor (2023). In February 2023, AstraZeneca completed its acquisition of CinCor Pharma. CinCor shareholders received non-tradeable milestone CVRs payable if a regulatory submission for a baxdrostat product is made by a specified time, with the CVRs representing about $1.8 billion in potential value.
Bristol-Myers Squibb and Celgene (2019). Celgene shareholders received cash, Bristol-Myers stock and an exchange-traded CVR that would pay $9 if three therapies won FDA approval by set deadlines. One approval came after its deadline, and the CVR terminated without paying.
Limitations and risks
- Unsecured and unguaranteed. The New York Stock Exchange treats CVRs as unsecured obligations of the issuer: holders have a contractual claim but no collateral, no claim on the company’s assets and no guaranteed payout. That puts them closer to option holders than to bondholders.
- Binary outcomes. Many CVRs pay in full or not at all, so an approval arriving even one month late can erase their value.
- Control sits with the acquirer. After closing, the buyer runs the business that determines whether the milestone is reached. Holders depend on the effort and timing obligations written into the agreement.
- Illiquidity. Non-transferable CVRs cannot be sold, so holders cannot exit early or lock in value.
- Valuation uncertainty. Because the true value at issuance is unclear, target shareholders may find it harder to judge whether the overall offer is fair.
CVRs vs. similar instruments
| Instrument | How it differs from a CVR |
|---|---|
| Earnout | Also contingent deal consideration, but typically used in private company sales and paid to a small group of sellers rather than public shareholders. |
| Stock option or warrant | Gives a right to buy shares at a set price; a CVR requires no purchase and pays only on its trigger. |
| Corporate bond | Promises scheduled interest and principal; a CVR promises nothing unless the condition is met. |
| Rights offering | Lets existing shareholders buy new shares, usually at a discount; it raises capital rather than settling a valuation dispute. |
FAQs
Is a CVR the same as owning stock?
No. A CVR carries no ownership, voting rights or dividends. It is a contractual right to a conditional payment, and if the condition is not met by the deadline, the holder keeps only the cash or shares received in the deal itself.
The Bottom Line
CVRs matter most to shareholders of acquisition targets and to investors weighing deals that include them. Treat only the cash or stock paid at closing as certain, and value the CVR by weighing the odds and timing of its trigger. Because CVRs are unsecured, often binary and controlled by the acquirer after closing, many expire worthless, as Celgene's CVR did.
